Please provide your email address to receive an email when new articles are posted on . Olokizumab demonstrated superiority compared with placebo and non-inferiority compared with adalimumab in ...

Ozoralizumab, in either the 30 mg or 80 mg formulation, significantly reduces rheumatoid arthritis signs and symptoms in patients with an inadequate response to methotrexate, according to data ...

SAN DIEGO, CA—Both fostamatinib regimens in the Oskira-1 Study achieved statistical improvements in ACR 20 response rate vs. placebo in patients treated with methotrexate, reported Michael Weinblatt, ...

March 5, 2003 — Using the data from a previously published efficacy trial, investigators compared an index of three core data from the ACR20 with the complete ACR20 and disease activity score. The ...

A new type of anti-interleukin-6 (IL-6) biologic called olokizumab was as effective as adalimumab (Humira) in rheumatoid arthritis patients who needed a step up from methotrexate monotherapy, results ...

January 11, 2010 (UPDATED January 13, 2010) — The US Food and Drug Administration (FDA) has approved tocilizumab intravenous infusion (Actemra, Roche) for the once-monthly treatment of moderately to ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window CHICAGO -- ...

First-in-class biologic therapy, IL-6 receptor-inhibiting monoclonal antibody approved based on largest clinical development program in rheumatoid arthritis to date Roche (SIX: RO, ROG; OTCQX: RHHBY) ...